Trial Profile
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGMS
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Sep 2023 This trial has been completed in Poland, according to European Clinical Trials Database.
- 09 Aug 2023 Planned End Date changed from 2 Nov 2028 to 12 Jul 2029.
- 19 Dec 2022 The trial has been restarted in Germany, according to European Clinical Trial registry record.